ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD
Overall ACAD gets a fundamental rating of 6 out of 10. We evaluated ACAD against 556 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make ACAD a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
ACAD had a positive operating cash flow in the past year.
ACAD had negative earnings in 4 of the past 5 years.
In multiple years ACAD reported negative operating cash flow during the last 5 years.
1.2 Ratios
ACAD has a Return On Assets of 20.23%. This is amongst the best in the industry. ACAD outperforms 97.49% of its industry peers.
The Return On Equity of ACAD (29.93%) is better than 97.67% of its industry peers.
ACAD's Return On Invested Capital of 9.30% is amongst the best of the industry. ACAD outperforms 94.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.23% | ||
| ROE | 29.93% | ||
| ROIC | 9.3% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 22.99%, ACAD belongs to the top of the industry, outperforming 95.69% of the companies in the same industry.
Looking at the Operating Margin, with a value of 8.84%, ACAD belongs to the top of the industry, outperforming 93.72% of the companies in the same industry.
With an excellent Gross Margin value of 92.08%, ACAD belongs to the best of the industry, outperforming 93.18% of the companies in the same industry.
ACAD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.84% | ||
| PM (TTM) | 22.99% | ||
| GM | 92.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
Compared to 5 years ago, ACAD has more shares outstanding
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ACAD has an Altman-Z score of 4.77. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.77, ACAD is in the better half of the industry, outperforming 76.84% of the companies in the same industry.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.77 |
ROIC/WACC0.97
WACC9.63%
2.3 Liquidity
A Current Ratio of 2.87 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a Current ratio of 2.87. This is in the lower half of the industry: ACAD underperforms 66.43% of its industry peers.
ACAD has a Quick Ratio of 2.80. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ACAD (2.80) is worse than 64.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.87 | ||
| Quick Ratio | 2.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 5000.00% over the past year.
The Revenue has grown by 22.39% in the past year. This is a very strong growth!
ACAD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.08% yearly.
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
3.2 Future
The Earnings Per Share is expected to grow by 44.65% on average over the next years. This is a very strong growth
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.99% yearly.
EPS Next Y17.36%
EPS Next 2Y35.61%
EPS Next 3Y45.23%
EPS Next 5Y44.65%
Revenue Next Year9.35%
Revenue Next 2Y9.97%
Revenue Next 3Y10.61%
Revenue Next 5Y10.99%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 42.76 indicates a quite expensive valuation of ACAD.
93.00% of the companies in the same industry are more expensive than ACAD, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.45, ACAD is valued quite expensively.
ACAD is valuated rather expensively with a Price/Forward Earnings ratio of 23.73.
ACAD's Price/Forward Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 91.56% of the companies in the same industry.
ACAD's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.90.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.76 | ||
| Fwd PE | 23.73 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 92.28% of the companies in the same industry.
91.92% of the companies in the same industry are more expensive than ACAD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 70.86 | ||
| EV/EBITDA | 35.56 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ACAD does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of ACAD may justify a higher PE ratio.
ACAD's earnings are expected to grow with 45.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.46
PEG (5Y)N/A
EPS Next 2Y35.61%
EPS Next 3Y45.23%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.95
-0.29 (-1.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.58%
Inst Owner Change-66.4%
Ins Owners0.31%
Ins Owner Change3.85%
Market Cap3.51B
Analysts76.15
Price Target27.54 (31.46%)
Short Float %9.31%
Short Ratio6.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.13%
Min EPS beat(2)-109.07%
Max EPS beat(2)-3.19%
EPS beat(4)2
Avg EPS beat(4)-15.12%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)7
Avg EPS beat(12)13.32%
EPS beat(16)10
Avg EPS beat(16)17.13%
Revenue beat(2)1
Avg Revenue beat(2)-4.13%
Min Revenue beat(2)-8.33%
Max Revenue beat(2)0.08%
Revenue beat(4)2
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.66%
Revenue beat(8)5
Avg Revenue beat(8)0.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.72%
Revenue beat(16)7
Avg Revenue beat(16)-1.86%
PT rev (1m)11.52%
PT rev (3m)8.69%
EPS NQ rev (1m)-2.3%
EPS NQ rev (3m)-18.19%
EPS NY rev (1m)-5.17%
EPS NY rev (3m)-14.8%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.76 | ||
| Fwd PE | 23.73 | ||
| P/S | 3.52 | ||
| P/FCF | 70.86 | ||
| P/OCF | 23.53 | ||
| P/B | 4.58 | ||
| P/tB | 5.41 | ||
| EV/EBITDA | 35.56 |
EPS(TTM)0.49
EY2.34%
EPS(NY)0.88
Fwd EY4.21%
FCF(TTM)0.3
FCFY1.41%
OCF(TTM)0.89
OCFY4.25%
SpS5.95
BVpS4.57
TBVpS3.87
PEG (NY)2.46
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.23% | ||
| ROE | 29.93% | ||
| ROCE | 10.62% | ||
| ROIC | 9.3% | ||
| ROICexc | 9.3% | ||
| ROICexgc | 10.83% | ||
| OM | 8.84% | ||
| PM (TTM) | 22.99% | ||
| GM | 92.08% | ||
| FCFM | 4.97% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score5
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 151.14% | ||
| Profit Quality | 21.61% | ||
| Current Ratio | 2.87 | ||
| Quick Ratio | 2.8 | ||
| Altman-Z | 4.77 |
F-Score5
WACC9.63%
ROIC/WACC0.97
Cap/Depr(3y)241.2%
Cap/Depr(5y)203.04%
Cap/Sales(3y)1.85%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y17.36%
EPS Next 2Y35.61%
EPS Next 3Y45.23%
EPS Next 5Y44.65%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
Revenue Next Year9.35%
Revenue Next 2Y9.97%
Revenue Next 3Y10.61%
Revenue Next 5Y10.99%
EBIT growth 1Y1912.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.12%
EBIT Next 3Y44.84%
EBIT Next 5Y49.94%
FCF growth 1Y188.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y367.79%
OCF growth 3YN/A
OCF growth 5YN/A